Enzyme immunoassay

Global Immunoassay Markets 2021-2028 - Introduction of PoC Rapid Tests and Automated Immunoassay Analyzers is Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Health, Other Health, Well, National Cancer Institute, CAGR, Myocardial infarction, Application, Antigen, EIA, Incidence, Enzyme immunoassay, POC, Antibody, SRL Diagnostics, COVID-19, Malaria, American Cancer Society, Death, RIA, Software, Infection, HIV, WHO, Reagent, USD, Cancer, Smartphone, ELISA, Awareness, Medical device, Vaccine, Dietary supplement, Technology

The global immunoassay market size is expected to reach USD 36.7 billion by 2028 and is expected to expand at a CAGR of 6.7% from 2021 to 2028.

Key Points: 
  • The global immunoassay market size is expected to reach USD 36.7 billion by 2028 and is expected to expand at a CAGR of 6.7% from 2021 to 2028.
  • The introduction of PoC rapid tests and automated immunoassay analyzers is driving the market growth.
  • In addition, the rising number of chronic and infectious diseases is also leading to high market growth.
  • Several smartphone-based devices and associated tools have emerged as next-generation point-of-care diagnostics or testing devices, boosting the market growth.

Global Immunoassay Systems Industry to 2027 - Increasing Incidence of Infectious Diseases Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, October 1, 2021
Health, Infectious Diseases, CAGR, Growth, Enzyme immunoassay, COVID-19, Pet

The "Immunoassay Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunoassay Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Immunoassay Systems estimated at US$21.7 Billion in the year 2020, is projected to reach a revised size of US$29.4 Billion by 2027, growing at a CAGR of 4.4% over the analysis period 2020-2027.
  • Enzyme Immunoassay, one of the segments analyzed in the report, is projected to record a 4.2% CAGR and reach US$8.8 Billion by the end of the analysis period.
  • In the global Rapid Tests segment, USA, Canada, Japan, China and Europe will drive the 4.6% CAGR estimated for this segment.

Europe Immunoassay Analyzers Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Health, General Health, Growth, Siemens Healthineers, Prevalence, CAGR, CE marking, Longevity, COVID-19, EIA, USD, RIA, Network analyzer (AC power), Diagnosis, Hospital, Research, Enzyme immunoassay, Medical device

The "Europe Immunoassay Analyzers Market Size, Share & Trends Analysis Report by Analyzers (Enzyme Immunoassay (EIA) Analyzers, Radioimmunoassay (RIA) Analyzers), by End Use and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Immunoassay Analyzers Market Size, Share & Trends Analysis Report by Analyzers (Enzyme Immunoassay (EIA) Analyzers, Radioimmunoassay (RIA) Analyzers), by End Use and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Europe immunoassay analyzers market size is expected to reach USD 2.6 billion by 2028, expanding at a CAGR of 6.0%
    The rising prevalence of chronic and infectious diseases and the approval and launch of innovative analyzers are major factors driving the market.
  • For instance, in February 2021, SysmexCorporation, a Japan-based immunoassay manufacturer, established its new subsidiary, Sysmex Portugal, S.A., in Portugal.
  • By end use, the hospitals segment held the largest revenue share in 2020, as hospitals are the primary centers for the diagnosis and treatment of chronic diseases
    Chapter 3 Europe Immunoassay Analyzers Market Variables, Trends & Scope

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Report 2021-2025: Market is Poised to Grow by $265.55 Million - Increase in Chronic Diseases Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Other Science, Science, Chemistry, Physical sciences, Laboratory techniques, Assay, Biochemistry, Titration, ELISA, ELISA, Branches of biology, Immunology, Enzyme immunoassay, Chlamydia antibodies

The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the enzyme-linked immunosorbent assay (Elisa) testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The enzyme-linked immunosorbent assay (Elisa) testing market analysis includes the end-user segment and geographic landscape.
  • This study identifies the increase in chronic diseases as one of the prime reasons driving the enzyme-linked immunosorbent assay (Elisa) testing market growth during the next few years.

Global COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Medical Device Pipeline Market Assessment 2020-2021 Featuring Over 120 Companies

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Immunologic tests, Clinical medicine, Medicine, Laboratory techniques, ELISA, Assay, ELISA, Immunology, Palaeoimmunology, Enzyme immunoassay

b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com\'s offering.\n"COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.\nCOVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity.

Key Points: 
  • b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com\'s offering.\n"COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.\nCOVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity.
  • They are used to detect the recombinant protein and peptide antigens in the samples.
  • ELISA\'s are specifically designed to screen large number of samples at a time.\nThe report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities\nIn-depth analysis of the product\'s current stage of development, territory and estimated launch date\n'

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

Immunoassay Market to Reach $43.51 Billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
Tuesday, March 30, 2021
Immunologic tests, Biochemistry methods, Chemistry, Physical sciences, Natural sciences, Immunoassay, ELISA, Assay, Siemens Healthineers, Enzyme immunoassay, DiaSorin

Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.

Key Points: 
  • Further, the continuous development of new biomarkers, cost-benefit, and growing adoption of automated platforms for ELISA are expected to increase immunoassay technology adoption.
  • Through all these advances, the usage of immunoassay is further expected to expand, supporting market growth in upcoming years.
  • On the basis of product and solution, the immunoassay kits and reagents segment accounted for the largest share of the overall immunoassays market.
  • For instance, in February 2021, Siemens Healthineers AG (Germany) received the CE mark approval for its SARS-CoV-2 Antigen Assay (CoV2Ag).

Global Enzyme-Linked Immunosorbent Assay Technologies Market Outlook to 2027 - Strategic Recommendations for New Entrants

Retrieved on: 
Monday, October 12, 2020
Medical specialties, Immunologic tests, Natural sciences, Clinical medicine, ELISA, Assay, ELISA, Enzyme immunoassay, NS1 antigen test

DUBLIN, Oct. 12, 2020 /PRNewswire/ -- The "Enzyme-Linked Immunosorbent Assay (ELISA) Technologies - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 12, 2020 /PRNewswire/ -- The "Enzyme-Linked Immunosorbent Assay (ELISA) Technologies - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Enzyme-Linked Immunosorbent Assay (ELISA) Technologies Market is expected to grow at a CAGR of 4.0% during the forecast period.
  • However, the high cost associated with the testing procedure is the restraining factor for the growth of the market.
  • Enzyme-Linked Immunosorbent Assay (ELISA) technologies are used to conduct tests to detect the presence of antibodies in a biological liquid sample.

Insights on the Enzyme-Linked Immunosorbent Assay Technologies Global Market to 2027 - Featuring ZEUS Scientific, Bio-Rad Laboratories & BioLegand Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 7, 2020
Infectious diseases, Biotechnology, Health, Oncology, Medical specialties, Immunologic tests, Natural sciences, Clinical medicine, Assay, Biochemistry, Titration, ELISA, ELISA, Enzyme immunoassay, NS1 antigen test

The "Enzyme-Linked Immunosorbent Assay (ELISA) Technologies - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enzyme-Linked Immunosorbent Assay (ELISA) Technologies - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Enzyme-Linked Immunosorbent Assay (ELISA) Technologies Market is expected to grow at a CAGR of 4.0% during the forecast period.
  • However, the high cost associated with the testing procedure is the restraining factor for the growth of the market.
  • Enzyme-Linked Immunosorbent Assay (ELISA) technologies are used to conduct tests to detect the presence of antibodies in a biological liquid sample.

Fujirebio Diagnostics Announces Initiation of Clinical Testing for the Fully Automated Lumipulse® SARS CoV-2 Antigen Assay

Retrieved on: 
Wednesday, August 5, 2020
Research, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, Medical Supplies, Practice Management, FDA, Other Science, Health, Natural sciences, Chemistry, Immunologic tests, Physical sciences, Biochemistry methods, Enzyme immunoassay, Immunoassay, Assay, Emergency Use Authorization, Medical laboratory, Innogenetics, Fujirebio Diagnostics, Inc., Fujirebio

Group Holdings, Inc., announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

Key Points: 
  • Group Holdings, Inc., announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.
  • The Lumipulse SARS-CoV-2 Antigen assay will be available for use on the LUMIPULSE G1200 instrument.
  • The LUMIPULSE G1200 is a robust, fully automated CLEIA (chemiluminescent enzyme immunoassay) immunoassay instrument.
  • Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.